| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
|
N Engl J Med
|
2007
|
24.19
|
|
2
|
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
|
N Engl J Med
|
2012
|
13.48
|
|
3
|
Phase I/II trial of tremelimumab in patients with metastatic melanoma.
|
J Clin Oncol
|
2009
|
2.53
|
|
4
|
Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.
|
PLoS One
|
2012
|
2.21
|
|
5
|
Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690.
|
Cancer
|
2002
|
2.00
|
|
6
|
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.
|
Nat Rev Clin Oncol
|
2013
|
1.46
|
|
7
|
The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study.
|
Clin Cancer Res
|
2006
|
1.08
|
|
8
|
A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma.
|
Cancer
|
2010
|
1.06
|
|
9
|
Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma.
|
Clin Cancer Res
|
2005
|
1.05
|
|
10
|
Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer.
|
Clin Cancer Res
|
2007
|
0.88
|
|
11
|
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors.
|
Invest New Drugs
|
2014
|
0.85
|
|
12
|
Dacarbazine induced acute myeloid leukemia in melanoma.
|
Melanoma Res
|
2009
|
0.76
|
|
13
|
Corrigendum: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance.
|
Nature
|
2016
|
0.75
|
|
14
|
Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
|
J Natl Compr Canc Netw
|
2017
|
0.75
|